1. Home
  2. RPD vs AMPH Comparison

RPD vs AMPH Comparison

Compare RPD & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rapid7 Inc.

RPD

Rapid7 Inc.

HOLD

Current Price

$15.63

Market Cap

1.0B

Sector

Technology

ML Signal

HOLD

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$25.58

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPD
AMPH
Founded
2000
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.3B
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
RPD
AMPH
Price
$15.63
$25.58
Analyst Decision
Hold
Buy
Analyst Count
21
6
Target Price
$24.00
$31.00
AVG Volume (30 Days)
1.2M
374.8K
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.35
2.27
Revenue
$858,667,000.00
$723,305,000.00
Revenue This Year
$2.63
$1.35
Revenue Next Year
$1.65
$5.10
P/E Ratio
$46.97
$11.14
Revenue Growth
3.08
N/A
52 Week Low
$13.21
$20.39
52 Week High
$42.09
$45.39

Technical Indicators

Market Signals
Indicator
RPD
AMPH
Relative Strength Index (RSI) 46.45 45.81
Support Level $15.73 $25.20
Resistance Level $16.88 $26.50
Average True Range (ATR) 0.54 0.80
MACD 0.14 -0.18
Stochastic Oscillator 22.32 13.07

Price Performance

Historical Comparison
RPD
AMPH

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Share on Social Networks: